AnaptysBio, Inc. — Earnings Quality Grade F
ANAB · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 53 days, change -110 days YoY
AR growth -17.0% vs revenue growth 157.0%
Revenue 157.0%, CFFO 114.6%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -75.7% vs revenue 157.0%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF $0.0B, FCF/NI = -1.48
Accruals ratio = -9.0%. Low accruals
Cash $0.3B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = 0.6x (<2x). Financial stress
Other assets 0.0% vs revenue 157.0%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor ANAB continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25